Immunoselection in vitro of a non-metastatic variant from a highly metastatic tumor.
Immunoselection of a non-metastatic variant of the highly metastatic MDAY-D2 tumor of DBA/2 mice was achieved by means of an antiserum directed to the LY6.2 surface marker of MDAY-D2. While the new tumor (MDAY-D2.L61) expresses no detectable LY6.2, other measurable surface markers including H2d, FcR and TAA remain unchanged. The phenotypic behavior of MDAY-D2.L61 is that of a non-metastatic tumor and has remained stable after 1 year of maintenance in vivo and in vitro. Immunoselection can now be used to derive variants with stable phenotypic behavior from heterogeneous parent tumor cell populations.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000954:Antigens, Surface / Q000276:immunology; D002460:Cell Line; D005260:Female; D051379:Mice; D008811:Mice, Inbred DBA; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000276:immunology; D010641:Phenotype; D013945:Thymoma / Q000276:immunology*
D000912:Antibodies, Neoplasm; D000954:Antigens, Surface